TNF and hepatocellular carcinoma: Considering that there are no pharmacological inhibitors specific to AATF, we hypothesized whether targeting an upstream molecule such as TNF‐α could offer a potential therapeutic strategy to prevent AATF‐mediated MASH‐HCC.